(Reuters) – Britain’s competition regulator said on Friday it has initiated a probe into U.S. medical equipment maker Thermo Fisher Scientific’s $3.1 billion deal to buy Swedish biotech firm Olink Holding AB.
The Competition and Markets Authority (CMA) has set a deadline of July 8 for its phase 1 decision.
(Reporting by Eva Mathews in Bengaluru; Editing by Shinjini Ganguli)
